patvann/titrate-glp1-agonist-dose

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

This phase 3 trial assessed the impact of continued tirzepatide treatment on maintaining weight loss in adults with obesity or overweight. After a 36-week lead-in period, participants were randomized to either continue tirzepatide or switch to placebo for 52 weeks. Those continuing tirzepatide maintained significant weight loss, with 89.5% retaining at least 80% of their initial loss, while the placebo group regained much of the weight. Common side effects were mild to moderate gastrointestinal issues.